Leanne M. Low
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leanne M. Low has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Danielle I. Stanisic
Institute for Biomedicine and Glycomics Griffith University Southport QLD Australia
5 shared publications - Michael F. Good
Griffith University
5 shared publications - Aloysious Ssemaganda
Department of National Health Laboratory and Diagnostics Services, Central Public Health Laboratories (NHLDS-CPHL), Ministry of Health, P.O. Box 7272, Kampala, Uganda
2 shared publications - Eric Calvo
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
2 shared publications - Louis H. Miller
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
2 shared publications Mei-Fong Ho
Institute for Glycomics, Griffith University, Gold Coast campus, Queensland, Australia
2 shared publications
Latest Publications
- Open Access
- 28 December 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (1)
The direct binding of Plasmodium vivax AMA1 to erythrocytes defines a RON2-independent invasion pathway
We used a transgenic parasite in which Plasmodium falciparum parasites were genetically modified to express Plasmodium vivax apical membrane antigen 1 (PvAMA1) protein in place of PfAMA1 to study PvAMA1-mediated invasion. In P. falciparum , AMA1 interaction with rhoptry neck protein 2 (RON2) is known to be crucial for invasion, and PfRON2 peptides (PfRON2p) blocked the invasion of PfAMA1 wild-type parasites. However, PfRON2p has no effect on the invasion of transgenic parasites expressing PvAMA1 indicating that PfRON2 had no role in the invasion of PvAMA1 transgenic parasites. Interestingly, PvRON2p blocked the invasion of PvAMA1 transgenic parasites in a dose-dependent manner. We found that recombinant PvAMA1 domains 1 and 2 (rPvAMA1) bound to reticulocytes and normocytes indicating that PvAMA1 directly interacts with erythrocytes during the invasion, and invasion blocking of PvRON2p may result from it interfering with PvAMA1 binding to erythrocytes. It was previously shown that the peptide containing Loop1a of PvAMA1 (PvAMA1 Loop1a) is also bound to reticulocytes. We found that the Loop1a peptide blocked the binding of PvAMA1 to erythrocytes. PvAMA1 Loop1a has no polymorphisms in contrast to other PvAMA1 loops and may be an attractive vaccine target. We thus present the evidence that PvAMA1 binds to erythrocytes in addition to interacting with PvRON2 suggesting that the P. vivax merozoites may exploit complex pathways during the invasion process.
- 28 December 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (1)
Open AccessThe direct binding of Plasmodium vivax AMA1 to erythrocytes defines a RON2-independent invasion pathway
We used a transgenic parasite in which Plasmodium falciparum parasites were genetically modified to express Plasmodium vivax apical membrane antigen 1 (PvAMA1) protein in place of PfAMA1 to study PvAMA1-mediated invasion. In P. falciparum , AMA1 interaction with rhoptry neck protein 2 (RON2) is known to be crucial for invasion, and PfRON2 peptides (PfRON2p) blocked the invasion of PfAMA1 wild-type parasites. However, PfRON2p has no effect on the invasion of transgenic parasites expressing PvAMA1 indicating that PfRON2 had no role in the invasion of PvAMA1 transgenic parasites. Interestingly, PvRON2p blocked the invasion of PvAMA1 transgenic parasites in a dose-dependent manner. We found that recombinant PvAMA1 domains 1 and 2 (rPvAMA1) bound to reticulocytes and normocytes indicating that PvAMA1 directly interacts with erythrocytes during the invasion, and invasion blocking of PvRON2p may result from it interfering with PvAMA1 binding to erythrocytes. It was previously shown that the peptide containing Loop1a of PvAMA1 (PvAMA1 Loop1a) is also bound to reticulocytes. We found that the Loop1a peptide blocked the binding of PvAMA1 to erythrocytes. PvAMA1 Loop1a has no polymorphisms in contrast to other PvAMA1 loops and may be an attractive vaccine target. We thus present the evidence that PvAMA1 binds to erythrocytes in addition to interacting with PvRON2 suggesting that the P. vivax merozoites may exploit complex pathways during the invasion process.
- 3 August 2022
- Published by Elsevier in Trends in Parasitology
- Vol. 38 (10) , 904-918
A vaccine for human babesiosis: prospects and feasibility
- 3 August 2022
- Published by Elsevier in Trends in Parasitology
- Vol. 38 (10) , 904-918
A vaccine for human babesiosis: prospects and feasibility
- 25 May 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (22)
Complement C1s cleaves PfEMP1 at interdomain conserved sites inhibiting Plasmodium falciparum cytoadherence
Significance: Mature asexual stages of Plasmodium falciparum -infected erythrocytes (IEs) bind to endothelium to avoid splenic clearance. The PfEMP1 family is the major cytoadhesion ligand at the IE surface and is essential for parasite sequestration. In this study, we show that complement component 1s (C1s), found in serum, cleaves PfEMP1 on the IEs to prevent binding to endothelial cells. We find that the C1s cleavage sites are maintained at semiconserved arginine motifs located at interdomain regions between PfEMP1 receptor-binding domains and upstream of the transmembrane region. This suggests that parasites have taken advantage of a human serum protease, either to escape antibody recognition of sequestered parasites or to dampen sequestration and pathogenesis from uncontrolled inflammatory responses threatening host survival.
- 25 May 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (22)
Complement C1s cleaves PfEMP1 at interdomain conserved sites inhibiting Plasmodium falciparum cytoadherence
Significance: Mature asexual stages of Plasmodium falciparum -infected erythrocytes (IEs) bind to endothelium to avoid splenic clearance. The PfEMP1 family is the major cytoadhesion ligand at the IE surface and is essential for parasite sequestration. In this study, we show that complement component 1s (C1s), found in serum, cleaves PfEMP1 on the IEs to prevent binding to endothelial cells. We find that the C1s cleavage sites are maintained at semiconserved arginine motifs located at interdomain regions between PfEMP1 receptor-binding domains and upstream of the transmembrane region. This suggests that parasites have taken advantage of a human serum protease, either to escape antibody recognition of sequestered parasites or to dampen sequestration and pathogenesis from uncontrolled inflammatory responses threatening host survival.
- Open Access
- 27 August 2019
- Published by American Society for Microbiology in mBio
- Vol. 10 (4) , e01460-19
Deletion of Plasmodium falciparum Protein RON3 Affects the Functional Translocation of Exported Proteins and Glucose Uptake
The malarial parasite within the erythrocyte is surrounded by two membranes. Plasmodium translocon of exported proteins (PTEX) in the parasite vacuolar membrane critically transports proteins from the parasite to the erythrocytic cytosol and membrane to create protein infrastructure important for virulence. The components of PTEX are stored within the dense granule, which is secreted from the parasite during invasion. We now describe a protein, RON3, from another invasion organelle, the rhoptry, that is also secreted during invasion. We find that RON3 is required for the protein transport function of the PTEX and for glucose transport from the RBC cytoplasm to the parasite, a function thought to be mediated by PTEX component EXP2.
- 27 August 2019
- Published by American Society for Microbiology in mBio
- Vol. 10 (4) , e01460-19
Open AccessDeletion of Plasmodium falciparum Protein RON3 Affects the Functional Translocation of Exported Proteins and Glucose Uptake
The malarial parasite within the erythrocyte is surrounded by two membranes. Plasmodium translocon of exported proteins (PTEX) in the parasite vacuolar membrane critically transports proteins from the parasite to the erythrocytic cytosol and membrane to create protein infrastructure important for virulence. The components of PTEX are stored within the dense granule, which is secreted from the parasite during invasion. We now describe a protein, RON3, from another invasion organelle, the rhoptry, that is also secreted during invasion. We find that RON3 is required for the protein transport function of the PTEX and for glucose transport from the RBC cytoplasm to the parasite, a function thought to be mediated by PTEX component EXP2.
- Open Access
- 1 January 2019
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 87 (1) , e00587-18
Controlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites
Naturally acquired immunity to malaria is robust and protective against all strains of the same species ofPlasmodium. This develops as a result of repeated natural infection, taking several years to develop.
- 1 January 2019
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 87 (1) , e00587-18
Open AccessControlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites
Naturally acquired immunity to malaria is robust and protective against all strains of the same species ofPlasmodium. This develops as a result of repeated natural infection, taking several years to develop.
- 1 October 2018
- Published by Elsevier in Microbes and Infection
- Vol. 20 (9-10) , 477-483
Exploiting the apicoplast: apicoplast-targeting drugs and malaria vaccine development
- 1 October 2018
- Published by Elsevier in Microbes and Infection
- Vol. 20 (9-10) , 477-483
Exploiting the apicoplast: apicoplast-targeting drugs and malaria vaccine development
- Open Access
- 1 January 2018
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 10 (3) , 444-454
Gold(i) phosphine compounds as parasite attenuating agents for malaria vaccine and drug development
The asexual blood-stagePlasmodiumparasite attenuating properties of gold(i) phosphine compounds are exploited in a novel strategy for malaria vaccine development.
- 1 January 2018
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 10 (3) , 444-454
Open AccessGold(i) phosphine compounds as parasite attenuating agents for malaria vaccine and drug development
The asexual blood-stagePlasmodiumparasite attenuating properties of gold(i) phosphine compounds are exploited in a novel strategy for malaria vaccine development.
- Open Access
- 23 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0150021
Pharmacology of the Adenosine A3 Receptor in the Vasculature and Essential Hypertension
Essential hypertension is considered to be a multifactorial disorder and its aetiology has yet to be clearly identified. As the adenosine receptors have a significant role in mediating vasodilation, alterations in their structures or signalling pathways may be involved in the development of hypertension. This study aimed to measure the expression of adenosine A3 receptors in a range of cardiovascular tissues and determine whether they could be altered with essential hypertension, and to functionally test responses to adenosine A3 receptor agonists in coronary blood vessels using the isolated perfused heart preparation. mRNA samples from cardiovascular tissues and a range of blood vessels were collected from 10 week old male spontaneously hypertensive rats and age-gender matched Wistar rats (n = 8). The Langendorff heart perfusion preparation was used to characterise adenosine A3 receptor mediated coronary vasodilation in the rat heart. Adenosine A3 receptor agonists induced coronary vasodilation. The expression of adenosine A3 receptors in cardiovascular tissues was altered in a tissue-specific pattern. Specifically, down-regulation of adenosine A3 receptor expression occurred in hypertensive hearts, which might be associated with attenuated vasodilator responses observed in coronary vessels to adenosine A3 receptor agonists. This study demonstrated alterations in the expression of adenosine A3 receptors occurred in a tissue specific mode, and reduced adenosine A3 receptor mediated coronary vasodilation in hearts from spontaneously hypertensive rats. Our findings with regard to changes in the adenosine A3 receptor in hypertensive hearts suggest that adenosine A3 receptor might play a role in the physiopathology of essential hypertension and potentially open the way to pharmacologic manipulation of vasomotor activity by the use of adenosine A3 receptor agonists.
- 23 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0150021
Open AccessPharmacology of the Adenosine A3 Receptor in the Vasculature and Essential Hypertension
Essential hypertension is considered to be a multifactorial disorder and its aetiology has yet to be clearly identified. As the adenosine receptors have a significant role in mediating vasodilation, alterations in their structures or signalling pathways may be involved in the development of hypertension. This study aimed to measure the expression of adenosine A3 receptors in a range of cardiovascular tissues and determine whether they could be altered with essential hypertension, and to functionally test responses to adenosine A3 receptor agonists in coronary blood vessels using the isolated perfused heart preparation. mRNA samples from cardiovascular tissues and a range of blood vessels were collected from 10 week old male spontaneously hypertensive rats and age-gender matched Wistar rats (n = 8). The Langendorff heart perfusion preparation was used to characterise adenosine A3 receptor mediated coronary vasodilation in the rat heart. Adenosine A3 receptor agonists induced coronary vasodilation. The expression of adenosine A3 receptors in cardiovascular tissues was altered in a tissue-specific pattern. Specifically, down-regulation of adenosine A3 receptor expression occurred in hypertensive hearts, which might be associated with attenuated vasodilator responses observed in coronary vessels to adenosine A3 receptor agonists. This study demonstrated alterations in the expression of adenosine A3 receptors occurred in a tissue specific mode, and reduced adenosine A3 receptor mediated coronary vasodilation in hearts from spontaneously hypertensive rats. Our findings with regard to changes in the adenosine A3 receptor in hypertensive hearts suggest that adenosine A3 receptor might play a role in the physiopathology of essential hypertension and potentially open the way to pharmacologic manipulation of vasomotor activity by the use of adenosine A3 receptor agonists.